US Stock Insider Trading | Neuronetics disclosed two insider trades on February 12

K-LinePoet · 2026-03-04T00:05:48+00:00

Neuronetics disclosed insider trading activity on February 12, 2026. Director Sullivan Keith J sold 41,000 shares on February 10 at a price of $1.55 per share. The company focuses on developing medical technologies that improve the quality of life for patients with mental health disorders.

K-LinePoet

2026-03-04 00:05:48

Abstract generation in progress

On February 12, 2026, Neuronetics (STIM) disclosed two insider trading transactions. Director Sullivan Keith J sold 41,000 shares on February 10, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 12, 2026	Director	Sullivan Keith J	February 10, 2026	Sell	41,000	1.55	63,500
February 12, 2026	Executive	MACAN WILLIAM ANDREW	February 10, 2026	Sell	3,485	1.55	5,401.75
August 12, 2025	Shareholder with >10% stake	Madryn Asset Management, LP	August 8, 2025	Sell	3,500,000	3.72	13,020,000
May 14, 2025	Executive	Furlong Stephen	May 13, 2025	Sell	6,540	4.16	20,200
May 14, 2025	Executive	Furlong Stephen	May 12, 2025	Sell	193,500	4.27	826,100
March 6, 2025	Executive	MACAN WILLIAM ANDREW	March 4, 2025	Sell	377	4.48	1,689
March 6, 2025	Executive	Furlong Stephen	March 4, 2025	Sell	1,867	4.48	8,364
February 20, 2025	Director	Sullivan Keith J	February 18, 2025	Sell	25,900	4.41	114,400
February 20, 2025	Director	Sullivan Keith J	February 19, 2025	Sell	24,400	4.70	114,800
February 18, 2025	Executive	Furlong Stephen	February 14, 2025	Sell	17,300	4.11	71,100

【Company Profile】

Neuronetics, Inc. was incorporated in Delaware in April 2003. The company is a commercial-stage medical technology firm focused on designing, developing, and selling products that improve the quality of life for patients with mental health conditions. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive, office-based treatment that uses transcranial magnetic stimulation (TMS) to create pulse MRI-strength magnetic fields, inducing currents designed to stimulate specific brain regions associated with mood. The U.S. Food and Drug Administration (FDA) has approved this system for treating adult patients with major depressive disorder (MDD) who have not responded satisfactorily to previous antidepressant medications during current depressive episodes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.